Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods – 11 February 2025

Overview

The Therapeutic Goods Act 1989 was enacted by the Parliament of Australia to regulate the supply and manufacturing of therapeutic goods, ensuring public safety and quality. The Act provides a framework for the regulation of therapeutic goods, including medicines, medical devices, and blood products, through licensing and other mechanisms to protect consumers from unsafe or substandard products. The Act was introduced to address the need for a comprehensive regulatory framework to manage the safety, efficacy, and quality of therapeutic goods in Australia. The Delegate of the Secretary of the Department of Health and Aged Care, Therapeutic Goods Administration, has the authority to revoke a licence to manufacture therapeutic goods under Section 41 of the Act. The policy objective of the Act is to safeguard public health by ensuring that therapeutic goods available in Australia are of acceptable quality and safety. On 11 February 2025, Katherine Clark, acting as the Delegate of the Secretary, published a notice under Section 41(1)(e) of the Therapeutic Goods Act 1989, revoking the licences of several manufacturers of therapeutic goods. The revocations were made at the request of the manufacturers themselves, including Pharmaceutical Packaging Professionals Pty Ltd, Global Medical Solutions Australia Pty Limited, Toll Transport Pty Ltd, and DHL Supply Chain Australia Pty Limited. This action highlights the importance of maintaining high standards in the manufacture of therapeutic goods and the enforcement mechanisms available to the Therapeutic Goods Administration to address non-compliance or other issues that may compromise public health.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration under the Department of Health and Aged Care, outlines the regulatory framework for therapeutic goods in Australia. The Act applies to entities that manufacture, package, label, import, or otherwise deal with therapeutic goods, ensuring that these products meet the necessary safety, quality, and efficacy standards before they are made available in the market. The geographic reach of the Act is national, applying to all therapeutic goods regardless of where they are manufactured or distributed within Australia. The revocation of manufacturing licenses, as seen in the Gazette publication, affects specific entities such as Pharmaceutical Packaging Professionals Pty Ltd, Global Medical Solutions Australia Pty Limited, Toll Transport Pty Ltd, and DHL Supply Chain Australia Pty Limited, all of which have had their licenses revoked at their request. The revocation process is conducted in accordance with Section 41 of the Act, highlighting the regulatory authority's power to enforce compliance and maintain the integrity of the therapeutic goods market. The Act's provisions can be further extended or restricted through subordinate instruments, thereby allowing for more nuanced and context-specific regulatory measures.

Key Provisions

Section 41 of the Therapeutic Goods Act 1989 allows the Secretary of the Department of Health and Aged Care to revoke a Licence to Manufacture Therapeutic Goods under certain circumstances, as evidenced in this gazetted notice. Specifically, this notice addresses the revocation of manufacturing licenses held by Pharmaceutical Packaging Professionals Pty Ltd t/a PCI Pharma Services, Global Medical Solutions Australia Pty Limited, Toll Transport Pty Ltd, and DHL Supply Chain Australia Pty Limited. Each of these revocations was carried out at the request of the respective manufacturers. The obligations imposed by the Act on the parties affected by these revocations include compliance with the terms of their manufacturing licenses. When a license is revoked, the holder must cease all activities related to the manufacture of therapeutic goods immediately. Additionally, they are required to return any relevant documentation, materials, or equipment associated with the manufacturing process to the Therapeutic Goods Administration, as stipulated by the Act. Failure to comply with the provisions of the Therapeutic Goods Act 1989, including the revocation of a manufacturing license, can result in various penalties. According to the Act, breaches can lead to both civil and criminal consequences. Civil penalties can include fines up to $1.1 million for corporations and $220,000 for individuals, as outlined in Section 83. Criminal penalties can also be imposed, with fines up to $6.6 million for corporations and $1.32 million for individuals under Section 84. Furthermore, imprisonment for up to five years can be imposed on individuals found guilty of offences under the Act, as per Section 86.